Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...

RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key drivers of some of the deadliest cancers, including nearly all pancreatic cancers, half of colorectal ...

Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers. RAS gene mutations are found in 20% of all ...

Analysis of the p53/BAX Pathway in Colorectal Cancer: Low BAX Is a Negative Prognostic Factor in Patients With Resected Liver Metastases PATIENTS AND METHODS: One hundred forty patients were analyzed.

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

Find a tumor in a human or rodent, and the chances are that lurking within it will be an activated ras gene. The cancer-police have been trailing it for the better part of two decades and the file of ...

Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...